



Ophthalmic Adverse Events following SARS-CoV-2 Vaccination

Guest Editor:

Dr. Rohan Bir Singh

1. Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA
2. Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands
3. Discipline of Ophthalmology and Visual Sciences, Faculty of Health and Medical Sciences, Adelaide Medical School, University of Adelaide, Adelaide, Australia

Deadline for manuscript submissions:

closed (31 December 2023)

Message from the Guest Editor

Dear Colleagues,

In December 2020, the largest global vaccination efforts were launched to limit the spread and clinical severity of SARS-CoV-2. Although the vaccines have been reported to be highly efficacious in limiting the impact of SARS-CoV-2, their swift development and emergency use authorizations limited the short and long-term evaluation of rare adverse events in real-world settings. Over the past 20 months, several reports and studies have highlighted the adverse events (such as myocarditis, Guillain–Barré syndrome, etc.) following the administration of these vaccines. In this special edition, we are compiling case reports, series, review articles and studies focused on ophthalmic adverse events following SARS-CoV-2 vaccinations.

The submissions may include:

1. Case of rare ophthalmic adverse events following vaccination
2. Studies reporting risk of ophthalmic adverse events following vaccine
3. Analysis of global databases reporting vaccine-associated ophthalmic adverse events
4. Review articles evaluating published literature on ocular adverse events with special emphasis on underlying potential mechanisms.

Dr. Rohan Bir Singh
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com